PDCD1 and neoplasm: Only one protocol (#3), in which anti-PD-1 mAb alone was started and then ZSTK474 plus anti-PD-1 mAb combination treatment was followed, showed a significantly efficient tumor growth inhibition and improved survival compared with either ZSTK474 or anti-PD-1 mAb alone (figure 1D and E).